Alzheimer’s disease (AD)is the most common cause of dementia, gradually damaging memory and thinking abilities until daily life is severely affected
While current drugs manage symptoms temporarily, they cannot stop the underlying neurodegeneration. Growing evidence shows that Mesenchymal Stem Cells (MSCs)—particularly from umbilical cord tissue—may modulate inflammation and stimulate repair.
At EDNA Wellness, we translate global research into safe, certified clinical practice using TISTR approved UC-MSC processing to ensure quality and credibility.
Understanding Alzheimer’s Disease
Alzheimer’s is characterized by abnormal accumulation of β-amyloid plaques and tau tangles within the brain. These disrupt communication between neurons and trigger progressive cell death. Typical symptoms include short-term memory loss, language difficulty, confusion, and behavioral changes. Most cases appear after age 60 and worsen over 8–12 years
Current Treatment Limitations
Approved medications (cholinesterase inhibitors and memantine) temporarily improve neurotransmission but do not halt neuronal death. Recent antibody therapies targeting amyloid show modest benefit and carry risk of brain swelling. Hence, research is pivoting toward cell-based and regenerative interventions.
How Stem Cells May Help
Mesenchymal stem cells offer a multi-pathway approach to neuroprotection:
- Immunomodulation and anti-inflammation – MSC secretions reduce microglial activation and cytokines such as IL-1β and TNF-α.
- Neurotrophic factor release – growth factors (BDNF, NGF, VEGF) support neuronal survival and synaptic connectivity.
- Amyloid clearance – MSC-derived exosomes enhance phagocytosis of β-amyloid plaques
- Neurogenesis – MSC signaling stimulates resident neural stem cells to form new connections
These mechanisms focus on stabilizing the brain environment rather than replacing neurons directly.
Scientific Evidence So Far
- Pre-clinical results: Animal studies show that intravenous or intracerebral MSC infusion improves memory tests and reduces amyloid load without tumor formation
- Phase I/II human trial: Patients receiving IV MSCs demonstrated safety and stabilized cognitive scores over six months.
- Recent review: Across 12 trials, MSCs were well tolerated and linked to improved Mini-Mental State Exam scores in mild AD.
Although long-term benefits require confirmation, these studies suggest stem-cell therapy can slow neuroinflammatory progression.
Treatment Routes and Protocols
| Route | Description | Benefits | Limitations |
| Intravenous (IV) | Systemic delivery for immune and vascular modulation | Minimally invasive, safe | Fewer cells reach the brain |
| Intrathecal (Spinal Injection) | Direct delivery into CSF | Higher CNS bioavailability | Requires lumbar puncture |
| Intranasal (Experimental ) | Non-invasive nasal delivery to olfactory region | Promising animal data | Still in research phase |
At EDNA Wellness, we select routes based on research evidence, disease stage, and patient safety. All UC-MSCs are manufactured in GMP-certified labs and dosed within peer-reviewed safety ranges.
Expected Outcomes
Patients may observe:
- Weeks 1–4: better sleep or alertness
- Months 2–6: slower cognitive decline and reduced irritability
- Beyond 6 months: stabilization of daily function and quality of life
Results vary by severity and comorbid conditions; EDNA Wellness sets realistic expectations based on clinical evidence
Safety Profile
Across published trials, no serious adverse events or tumor formation were reported. Mild headache or fatigue after intrathecal injection can occur but resolves within days.
EDNA Wellness adheres to strict sterility and batch-testing standards to ensure each cell infusion is safe and traceable.
Cautions for Patients
- Verify that your doctor is a neurologist or board-certified regenerative specialist.
- Ask for the cell count, source, and certificate from a recognized lab.
- Avoid clinics that mix low-cell doses with steroids or promise instant memory recovery.
- Expect gradual, research-aligned progress — not miracle claims.
Stem-cell therapy is redefining hope for Alzheimer’s patients. While not a cure, UC-MSC therapy provides a scientifically supported method to calm neuro-inflammation and support brain health.
References
- Choi, H., Kim, Y., & Park, S. (2024). Clinical safety and cognitive outcomes after intravenous MSC therapy in mild Alzheimer’s patients. Frontiers in Aging Neuroscience, 16, 135-146.
- Kim, H. J., Lee, M. J., & Oh, S. H. (2022). Mesenchymal stem cell infusion improves cognitive function in patients with mild to moderate Alzheimer’s disease: A phase I/II study. Stem Cells Translational Medicine, 11(8), 789–798.
- Mayo Clinic. (2024). Alzheimer’s disease overview. Rochester, MN.
- National Institute on Aging. (2024). What is Alzheimer’s disease? U.S. Department of Health and Human Services.
- Zhang, L., Wang, P., & Chen, X. (2023). Mesenchymal stem cells ameliorate cognitive impairment and synaptic loss in Alzheimer’s models via anti-inflammatory mechanisms. Stem Cell Research & Therapy, 14(1), 102.